Glucocorticoid signalling is a common target for pharmaceutical intervention in certain conditions such as in the treatment of chronic inflammation [37]) or anxiety and depression [38]) and GR agonists and antagonists are commonly used as treatments in a wide range of clinical settings. This evidence concerns the gene NR3C1 and major depressive disorder.